山东步长制药股份有限公司关于为公司控股子公司提供担保的公告

Group 1 - The company has provided a guarantee of 30 million RMB for its subsidiary, Beijing Boyuan Runbu Pharmaceutical Research Co., Ltd., in a contract with Beijing Bank [2][6] - The board of directors approved a total financing limit of 6.92 billion RMB for the company and its subsidiaries for 2025, with specific limits for subsidiaries based on their debt-to-asset ratios [2][9] - The guarantee is deemed necessary for the subsidiary's operational needs and is expected to positively impact the company's development and efficiency [8][9] Group 2 - The company anticipates a net profit of approximately 320 million to 468 million RMB for the year 2025, marking a turnaround from a loss in the previous year [14][16] - The expected profit improvement is attributed to a decrease in goodwill impairment, an increase in drug sales, and a reduction in production costs [15][20] - The previous year's net loss was reported at approximately 553.8 million RMB, indicating a significant recovery in the current financial outlook [18][19]